Whether Hippo pathway dysregulation correlates with VHL, SETD2, or BAP2 mutations during RCC, and/or YAP/TAZ activation in such settings increases the risk of disease development, requires additional studies. The gene discussed is YAP1; the disease is renal cell carcinoma.